Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (2019 - 2021)

Historic Shares Outstanding for Lyell Immunopharma (LYEL) over the last 3 years, with Q4 2021 value amounting to $242.7 million.

  • Lyell Immunopharma's Shares Outstanding rose 145901.09% to $242.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $242.7 million, marking a year-over-year increase of 145901.09%. This contributed to the annual value of $242.7 million for FY2021, which is 145901.09% up from last year.
  • As of Q4 2021, Lyell Immunopharma's Shares Outstanding stood at $242.7 million, which was up 145901.09% from $239.8 million recorded in Q3 2021.
  • In the past 5 years, Lyell Immunopharma's Shares Outstanding ranged from a high of $242.7 million in Q4 2021 and a low of $11.2 million during Q4 2019
  • Its 3-year average for Shares Outstanding is $149.6 million, with a median of $238.5 million in 2021.
  • As far as peak fluctuations go, Lyell Immunopharma's Shares Outstanding surged by 3925.41% in 2020, and later surged by 145901.09% in 2021.
  • Lyell Immunopharma's Shares Outstanding (Quarter) stood at $11.2 million in 2019, then soared by 39.25% to $15.6 million in 2020, then skyrocketed by 1459.01% to $242.7 million in 2021.
  • Its last three reported values are $242.7 million in Q4 2021, $239.8 million for Q3 2021, and $238.5 million during Q2 2021.